Biodexa Pharmaceuticals (BDRX) News Today $6.59 -0.16 (-2.37%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$6.60 +0.01 (+0.09%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Biodexa announces enrollment of first two patients in Phase 3 Serenta trialAugust 19, 2025 | msn.comBiodexa Pharmaceuticals Begins Phase 3 Trial for FAP TreatmentAugust 19, 2025 | msn.comBiodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)August 18, 2025 | globenewswire.comADR Ratio Change EffectiveJuly 31, 2025 | globenewswire.comADR Ratio ChangeJuly 15, 2025 | globenewswire.comBiodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)July 14, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC Announces Successful Outcome of Annual General Meeting - NasdaqJune 29, 2025 | nasdaq.comBiodexa Pharmaceuticals PLC: Results of Annual General MeetingJune 27, 2025 | finanznachrichten.deResults of Annual General MeetingJune 27, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC: Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deBiodexa Activates First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis - NasdaqJune 26, 2025 | nasdaq.comBiodexa Pharmaceuticals Plc (BDRX) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comBiodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)June 25, 2025 | globenewswire.comBiodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - MorningstarJune 24, 2025 | morningstar.comMBiodexa Pharmaceuticals Announces "Serenta" as the Name for its Phase 3 Study in Familial Adenomatous Polyposis (FAP) - NasdaqJune 24, 2025 | nasdaq.comBiodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)June 23, 2025 | globenewswire.comBiodexa Pharmaceuticals: Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a StudyJune 18, 2025 | finanznachrichten.deResult of General MeetingJune 11, 2025 | globenewswire.comBiodexa Pharmaceuticals Initiates Phase 2 Study for Type 1 Diabetes TreatmentJune 4, 2025 | msn.comBiodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 DiabetesJune 4, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC: Shareholder UpdateMay 30, 2025 | finanznachrichten.deShareholder UpdateMay 30, 2025 | globenewswire.comBiodexa Pharmaceuticals (NASDAQ:BDRX) Trading 6.9% Higher - Still a Buy?May 25, 2025 | marketbeat.comBiodexa Pharma Secures Additional $3M CPRIT Grant To Advance ERapa Phase 3 Program In FAPMay 24, 2025 | nasdaq.comBiodexa secures additional $3M for cancer drug trialMay 23, 2025 | investing.comBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General MeetingMay 22, 2025 | globenewswire.comBiodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0MMay 22, 2025 | globenewswire.comBiodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMay 20, 2025 | msn.comBiodexa Pharmaceuticals PLC: Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAPMay 12, 2025 | finanznachrichten.deBiodexa Receives Orphan Drug Designation in Europe for eRapa in FAPMay 12, 2025 | globenewswire.comResult of General MeetingMay 2, 2025 | globenewswire.comBiodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest UpdateApril 29, 2025 | marketbeat.comWhat Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy StockApril 24, 2025 | msn.comBiodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 3.5% - Time to Sell?April 23, 2025 | marketbeat.comNotice of General MeetingApril 17, 2025 | globenewswire.comPreliminary Results for the Year Ended 31 December 2024April 11, 2025 | globenewswire.comPromising Nanotechnology Stocks To Watch Now - March 19thMarch 20, 2025 | marketbeat.comBiodexa says on track to initiate Phase 3 trial in FAP next quarterMarch 20, 2025 | markets.businessinsider.comShort Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Declines By 23.2%March 17, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC Achieves Key Milestone with FDA Following Type C Meeting for Phase 3 eRapa Study in Familial Adenomatous PolyposisMarch 12, 2025 | nasdaq.comBiodexa Pharma To Initiate Registrational Phase 3 Study Of ERapa In FAP In Next QuarterMarch 12, 2025 | nasdaq.comBest Nanotechnology Stocks To Consider - March 10thMarch 11, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPMarch 10, 2025 | finanznachrichten.deBiodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapaMarch 10, 2025 | markets.businessinsider.comBiodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPMarch 10, 2025 | globenewswire.comBiodexa Pharmaceuticals announces appointment of Precision for Medicine as CROMarch 6, 2025 | markets.businessinsider.comBiodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAPMarch 6, 2025 | globenewswire.comBiodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Increase in Short InterestFebruary 28, 2025 | marketbeat.comBiodexa Pharmaceuticals PLC: Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and UseFebruary 24, 2025 | finanznachrichten.deBiodexa Pharmaceuticals announces allowance of U.S. patent covering eRapaFebruary 24, 2025 | markets.businessinsider.com Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDRX Media Mentions By Week BDRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDRX News Sentiment▼0.000.71▲Average Medical News Sentiment BDRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDRX Articles This Week▼31▲BDRX Articles Average Week Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cocrystal Pharma News Today Mannatech News Today Pulmatrix News Today Hoth Therapeutics News Today X4 Pharmaceuticals News Today Lipocine News Today Lixte Biotechnology News Today NeuroSense Therapeutics News Today LakeShore Biopharma News Today Abpro News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access